Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE
ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We investigated which urinary proteins and pathways are associated with progressive kidney disease and canagliflozin treatment. Materials and Methods This case–control study included patients from the CREDENCE trial. Cases and controls were defined by annual eGFR decline of ≥ 5 or < 1 mL/min/1.73 m 2 and propensity score‐matched within treatment arms. High‐throughput urinary proteomics (SomaLogic, n = 5284 aptamers) was performed at baseline and year 1. Differential abundance analysis assessed 1‐year changes between cases and controls, and between canagliflozin and placebo‐treated patients. Identified proteins were mapped to kidney biopsy single‐cell RNA sequencing (scRNA‐seq) data from patients with type 2 diabetes, with or without SGLT2i treatment to identify cell type‐specific expression. Results Of 392 included participants, 250 were randomized to canagliflozin and 142 to placebo. After 1 year, 124 proteins were changed by canagliflozin compared to placebo (92 increased and 32 decreased). Enolase 1, SLIT, NTRK Like Family Member 1, and leucine‐rich repeat containing 15 increased more than 3‐fold, while decreases were observed in alanyl aminopeptidase, discoidin domain receptor 1 and ameloblastin. Pathway analysis revealed enhanced activity of metabolic pathways. scRNA‐seq data showed increased expression of metabolic genes after SGLT2i treatment in distal tubular cells. Conclusion These findings suggest that SGLT2i administration induces a redistribution of tubular workload through compensatory sodium reabsorption in distal parts of the nephron, which may contribute to kidney‐protective effects in DKD.
Authors
- Michael K. Hansen (ORCID: https://orcid.org/0000-0002-0062-0520)
- Niels Jongs (ORCID: https://orcid.org/0000-0002-0882-3656)
- Viji Nair (ORCID: https://orcid.org/0000-0003-1657-954X)
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Petter Bjornstad (ORCID: https://orcid.org/0000-0002-5160-2947)
- Edgar A. Otto (ORCID: https://orcid.org/0000-0002-2387-9973)
- Matthias Kretzler (ORCID: https://orcid.org/0000-0003-4064-0582)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Rajasree Menon (ORCID: https://orcid.org/0000-0001-6280-9639)
- Wenjun Ju (ORCID: https://orcid.org/0000-0002-9136-8454)
- Mark André de la Rambelje (ORCID: https://orcid.org/0009-0002-4083-0087)
Institutions
- University Medical Center Groningen (NL)
- University of Washington (US)
- University of Michigan (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1111/dom.71518
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00